22/6/2021 Covid-19 vaccination: What’s the evidence for extending the dosing interval?

| The BMJ

Intended for healthcare professionals

News
News Analysis

Covid-19 vaccination: What’s the evidence for extending the

dosing interval?
BMJ
2021;
372
doi: https://doi.org/10.1136/bmj.n18
(Published 06 January 2021)
Cite this as: BMJ 2021;372:n18

Read our latest coverage of the coronavirus outbreak

Opinion
Covid-19 vaccines: to delay or not to delay second doses

Opinion
How do you take your vaccine—one lump or two?

Gareth Iacobucci, Elisabeth Mahase

The BMJ

On 30 December the four UK chief medical officers announced that the second doses of the covid vaccines should be given
towards the end of 12 weeks rather than in the previously recommended 3-4 weeks. Gareth Iacobucci and Elisabeth Mahase
look at the questions this has raised

Why has the government taken the step to delay the second dose?
In a letter sent to healthcare staff on 30 December NHS England said the decision had been taken to prioritise giving theI first Accept
Cookies and privacy
doses of vaccine (whether the Pfizer and BioNTech one or that of Oxford University and AstraZeneca) to as many people as
We and
possible on our
thepartners store
priority list to and/or access
“protect information
the greatest on a device,
number such
of at-risk as unique
people IDsininthe
overall cookies to process
shortest possible time.”1 Delaying the
personal data. You may accept or manage your choices by clicking below, including your right to object where Show Purpose
second dose meant that the prioritisation process “will have the greatest impact on reducing mortality, severe disease and
legitimate interest
hospitalisations is protecting
and in used, or at the
any NHS
time in theequivalent
and privacy policy page.
health These choices
services,” it said.will be signaled to our
partners and will not affect browsing data. Cookie policy

Why was
We and this decision
our partners process data totaken?
provide:
In a Store
letterand/or
to the access
profession sent onon31a December
information laying outads
device, Personalised theand
“scientific
content,and public
ad and health
content rationale” for the change to the dosing
measurement,
audiencethe
schedule,2 insights
chief and product
medical development, Use
officers precise
said that vaccine geolocation
shortages weredata, Actively scan for
a major reason device
the characteristics
shift in approach. “We have to
for identification
ensure that we maximise the number of eligible people who receive the vaccine. Currently the main barrier to this is vaccine
availability, a global (vendors)
List of Partners issue, and this will remain the case for several months and, importantly, through the critical winter period. The

https://www.bmj.com/content/372/bmj.n18.full.print 1/5
22/6/2021 Covid-19 vaccination: What’s the evidence for extending the dosing interval? | The BMJ

availability of the AZ [AstraZeneca] vaccine reduces, but does not remove, this major problem. Vaccine shortage is a reality that
cannot be wished away.”

What’s the evidence for changing the schedule?

There isn’t much for the Pfizer-BioNTech vaccine, as trials did not compare different dose spacing or compare one with two doses.
The trials of the Oxford-AstraZeneca vaccine did include different spacing between doses, finding that a longer gap (two to three
months) led to a greater immune response, but the overall participant numbers were small. In the UK study 59% (1407 of 2377) of
the participants who had two standard doses received the second dose between nine and 12 weeks after the first. In the Brazil
study only 18.6% (384 of 2063) received a second dose between nine and 12 weeks after the first.3 The combined trial results,
published in the Lancet,4 found that vaccine efficacy 14 days after a second dose was higher in the group that had more than six
weeks between the two doses (65.4%) than in the group that had less than six weeks between doses (53.4%).

In their joint statement the chief medical officers said that data provided to the Medicines and Healthcare Products Regulatory
Agency (MHRA) showed that, although optimal efficacy was achieved through two doses, both vaccines “offer considerable
protection after a single dose, at least in the short term.”

Stephen Evans, professor of pharmacoepidemiology at the London School of Hygiene and Tropical Medicine, said, “In an ideal
world, decisions about treatments would only be made within the exact parameters of the trials which have been conducted. In the
real world, this is never so . . . We know that vaccinating only half of a vulnerable population will lead to a notable increase in
cases of covid-19, with all that this entails, including deaths. When resources of doses and people to vaccinate are limited, then
vaccinating more people with potentially less efficacy is demonstrably better than a fuller efficacy in only half.”

How effective is just one dose?

A paper published in the New England Journal of Medicine stated that the efficacy of the Pfizer-BioNTech vaccine was 52.4%
between the first and second dose (spaced 21 days apart).5 However, in its “green book” Public Health England said that during
the phase III trial most of the vaccine failures were in the days immediately after the first dose, indicating that the short term
protection starts around day 10.6 Looking at the data from day 15 to 21, it calculated that the efficacy against symptomatic covid-
19 was around 89% (95% confidence interval 52% to 97%). Meanwhile, Pfizer has said that it has no evidence that the protection
lasts beyond the 21 days.

In the case of the Oxford-AstraZeneca vaccine, PHE said, “High protection against hospitalisation was seen from 21 days after
dose one until two weeks after the second dose, suggesting that a single dose will provide high short term protection against
severe disease . . . An exploratory analysis of participants who had received one standard dose of the vaccine suggested that
efficacy against symptomatic covid-19 was 73% (95% CI 48.79-85.76%).”

What do the manufacturers say?

In a joint statement Pfizer and BioNTech said, “The safety and efficacy of the vaccine has not been evaluated on different dosing
schedules as the majority of trial participants received the second dose within the window specified in the study design . . . There
is no data to demonstrate that protection after the first dose is sustained after 21 days.”
I Accept
Cookies and privacy
The European Medicines Agency has said that the gap between the first and second doses of the Pfizer-BioNTech vaccine should
We and our
not exceed partners
42 days. store
“Any and/ortoaccess
change information
this would requireonaavariation
device, such asmarketing
to the unique IDsauthorisation
in cookies to process
as well as more clinical data to
personal data. You may accept or manage your choices by clicking below, including your right to object where Show Purpose
support such a change, otherwise it would be considered as ‘off-label use,’” the agency said.7
legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our
partners and
AstraZeneca didwill
notnot affect
reply browsing
to a requestdata. Cookie policy
for comment from The BMJ.

We and our partners process data to provide:

How have doctors responded?
Store and/or access information on a device, Personalised ads and content, ad and content measurement,
Theaudience
BMA hasinsights
called and
the government’s decision “unreasonable
product development, Use and totally
precise geolocation unfair” and
data, Actively scansaid it could
device cause “huge logistical problems”
characteristics
for general practices and vaccination centres.8 GPs and clinical leaders have told the BMA that delaying already promised second
for identification
doses
List“will have a terrible
of Partners impact on the emotional wellbeing of their most vulnerable, at-risk patients.”
(vendors)

https://www.bmj.com/content/372/bmj.n18.full.print 2/5
22/6/2021 Covid-19 vaccination: What’s the evidence for extending the dosing interval? | The BMJ

Richard Vautrey, chair of the BMA’s General Practitioners Committee, said, “The decision to ask GPs, at such short notice, to
rebook patients for three months hence will also cause huge logistical problems for almost all vaccination sites and practices. For
example, to make contact with even just 2000 elderly or vulnerable patients will take a team of five staff at a practice about a
week, and that’s simply untenable.”

He said that bookings for the oldest and most vulnerable members should be honoured.

Will the consent forms still be valid?

GPs told The BMJ that patients consent to the two doses of the vaccine during their appointment for the first dose but could not
specify what these changes would mean for that consent. They said that patients were understandably worried about the change
and called on the government to provide them with a clear explanation as to why this has happened.

What are patients told about their behaviour after one dose?
Patients are given a leaflet when attending vaccine appointments,9 and this has been updated to reflect the latest changes to
dosing. It tells patients that it takes one to two weeks for protection to build after the first dose. It advises, “Like all medicines, no
vaccine is completely effective, so you should continue to take recommended precautions to avoid infection. Some people may
still get covid-19 despite having a vaccination, but this should be less severe.”

How do other countries view the policy change?

The US news site STAT referred to the move as “effectively turning [the UK] into a living laboratory.”10 It accused the UK of basing
its new vaccination schedule “on small slices of evidence mined from ‘subsets of subsets’ of participants in clinical trials . . . and
on general principles of vaccinology rather than on actual research into the specific vaccines being used.” It added, “If the efforts
succeed, the world will have learnt a great deal. If they fail, the world will also have gained important information, though some
fear it could come at a high cost.”

But Andrew Pollard, the head of the Oxford Vaccine Group and chief investigator into the trial of this vaccine, said that extending
the gap between vaccines made biological sense. “Generally, a longer gap between vaccine doses leads to a better immune
response, with the second dose causing a better boost. (With HPV vaccine for girls, for example, the gap is a year and gives
better responses than a one month gap.) From the Oxford vaccine trials, there is 70% protection after the first dose up to the
second dose, and the immune response was about three times greater after the second dose when the second dose was
delayed, comparing second dose after four weeks versus second dose after 2-3 months,” he told The BMJ, referring to the
MHRA’s summary of product characteristics.11

“With the Pfizer vaccine, there are no published data comparing shorter and longer gaps between doses because all participants
had the second dose at 3-4 weeks. However, the biology is straightforward and will be the same as with all vaccines . . . The
immune system remembers the first dose and will respond whether the later dose is at three weeks or three months.”

In a statement the British Society for Immunology said, “Most immunologists would agree that delaying a second ‘booster’ dose of
a protein antigen vaccine (such as the two approved covid-19 vaccines) by eight weeks would be unlikely to have a negative
I Accept
effect on the overall immune response post-boost. We also would not expect any specific safety issues to arise for the individual
Cookies and privacy
due to delaying the second dose, other than an increased potential risk of disease during the extended period due to lowered
We and our partners store and/or access information on a device, such as unique IDs in cookies to process
protection.”
personal data. You may accept or manage your choices by clicking below, including your right to object where Show Purpose
However in a interest
legitimate BMJ Opinion
is used,article John
or at any Robertson,
time professor
in the privacy of surgery
policy page. Theseatchoices
the University of Nottingham,
will be signaled to our and colleagues, warned
partners and will not affect browsing data. Cookie policy
that less was known about the behaviour of the Pfizer vaccine because of the novel mRNA technology it uses.12 “Maximising
coverage with the first dose as intended by the CMOs could come at increased risk to already high risk/priority groups,” they said.
We and our partners process data to provide:
They called for the second dose of this vaccine to be provided at day 21 “until the MHRA and/or JCVI [Joint Committee on
Store and/or
Vaccination and access information
Immunisation] on athe
make device, Personalised
data on which theads and
JCVI content, ad and content
recommendation measurement,
is based publicly available for independent
audience insights and product development, Use precise geolocation data, Actively
scientific review” and for randomised controlled trials to compare the dosing schedules. scan device characteristics
for identification
List of Partners (vendors)

https://www.bmj.com/content/372/bmj.n18.full.print 3/5
22/6/2021 Covid-19 vaccination: What’s the evidence for extending the dosing interval? | The BMJ

A spokesperson for the Department of Health and Social Care for England said, “As agreed by all four UK chief medical officers
and the medical experts at the independent Joint Committee on Vaccination and Immunisation, the data provided by the
manufacturers demonstrated that both vaccines offer considerable protection for patients after the first dose.

“This measure will have the greatest impact on reducing mortality, severe disease, and hospitalisations, helping to protect the
NHS and save lives.”

Are any other countries going to do the same?

German health minister Jens Spahn has reportedly asked the Robert Koch Institute, the country’s disease control agency, to look
into extending the period between the first and second vaccine dose, according to the Guardian.13 Meanwhile, in Denmark the
infectious disease institute has said it was closely monitoring the UK situation and was considering a three to six week interval
between doses.

Could the gap lead to vaccine resistant strains of SARS-CoV-2?

Paul Bieniasz, a retrovirologist from Rockefeller University who is studying how the virus can acquire mutations, has warned that
the UK was taking a gamble that risked fostering vaccine resistant forms of the virus. He told the news site STAT, “My concern, as
a virologist, is that if you wanted to make a vaccine-resistant strain, what you would do is to build a cohort of partially immunized
individuals in the teeth of a highly prevalent viral infection.”14

When asked about this concern, a Department of Health and Social Care spokesperson did not directly answer the question,
saying rather that it was “vital we do everything we can to quickly and safely protect as many vulnerable people as possible from
this virus” and that data from manufacturers showed considerable protection for patients after the first dose.

What are the implications of this move for vaccine uptake?

Some experts are concerned that having large numbers of people only partially protected for several months could lead to some
individuals contracting covid while they wait for the second dose, which could dent people’s confidence in the effectiveness of
vaccines.

The British Society for Immunology has called on the government’s advisory committee on vaccines to make the “full evidence for
decisions around covid-19 vaccines available immediately” to build public trust. “Having access to the evidence and rationale
behind the public health decisions taken is important,” it said in a statement.15 “The government have confirmed that openness
and transparency are vital. The British Society for Immunology will continue to monitor and advocate for this.”

This article is made freely available for use in accordance with BMJ's website terms and conditions for the duration of the covid-19
pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial
purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

References
I Accept
Cookies and privacy
1. NHS. Letter to chief executives of all NHS trusts and foundation trusts. 30 Dec 2020. https://www.england.nhs.uk/coronavirus/wp-
Wecontent/uploads/sites/52/2020/12/C0994-System-letter-COVID-19-vaccination-deployment-planning-30-December-2020.pdf.
and our partners store and/or access information on a device, such as unique IDs in cookies to process
Show Purpose
2.personal data.forYou
Department mayand
Health accept or manage
Social yourtochoices
Care. Letter by clicking
the profession frombelow,
the UKincluding your officers
chief medical right to object where
regarding the UK covid-19 vaccination
legitimate interest
programmes. is used,
31 Dec 2020.orhttps://www.gov.uk/government/publications/letter-to-the-profession-from-the-uk-chief-medical-officers-on-the-
at any time in the privacy policy page. These choices will be signaled to our
partners and will not affect browsing data. Cookie policy
uk-covid-19-vaccination-programmes/letter-to-the-profession-from-the-uk-chief-medical-officers-regarding-the-uk-covid-19-vaccination-
programmes.
We and our partners process data to provide:
3. Supplementary appendix. https://www.thelancet.com/cms/10.1016/S0140-6736(20)32661-1/attachment/4fb6f146-1b38-48e0-89cb-
Store and/or access information on a device, Personalised ads and content, ad and content measurement,
213bc4dca7ec/mmc1.pdf.
audience insights and product development, Use precise geolocation data, Actively scan device characteristics
4. Voysey M, Clemens SAC, Madhi SA, et al., Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine
for identification
(AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
List of Partners (vendors)
Lancet2020;S0140-6736(20)32661-1. doi:10.1016/S0140-6736(20)32661-1. pmid:33306989

https://www.bmj.com/content/372/bmj.n18.full.print 4/5
22/6/2021 Covid-19 vaccination: What’s the evidence for extending the dosing interval? | The BMJ

5. Polack FP, Thomas SJ, Kitchin N, et al., C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N
Engl J Med2020;383:2603-15. doi:10.1056/NEJMoa2034577. pmid:33301246
6. Greenbook chapter 14a: Covid-19—SARS-CoV-2.
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948757/Greenbook_chapter_14a_v4.pdf.

7. EU says interval between Pfizer vaccine doses should be respected. Reuters. 4 Jan 2020. https://www.reuters.com/article/us-health-
coronavirus-ema-pfizer-idUSKBN2991Z3.
8. Mahase E. Covid-19: Order to reschedule and delay second vaccine dose is “totally unfair,” says BMA. BMJ2020;371:m4978.
doi:10.1136/bmj.m4978 pmid:33384299

9. Public Health England. Covid-19 vaccination: what to expect.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/948780/PHE_11920_Covid-
19_what_to_expect_v2.pdf.
10. Branswell H. Britain takes a gamble with Covid-19 vaccines, upping the stakes for the rest of us. 4 Jan 2021.
https://www.statnews.com/2021/01/04/britain-takes-a-gamble-with-covid-19-vaccines-upping-the-stakes-for-the-rest-of-us.

11. Medicines and Healthcare Products Regulatory Agency. Information for healthcare professionals on covid-19 vaccine AstraZeneca. 5 Jan
2020. https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-
professionals-on-covid-19-vaccine-astrazeneca.
12. Robertson J, et al. Covid-19 vaccines: to delay or not to delay second doses. BMJ Opinion. 5 Jan 2020.
https://blogs.bmj.com/bmj/2021/01/05/covid-19-vaccines-to-delay-or-not-to-delay-second-doses.

13. Henley J, Oltermann P, Willsher K. Germany and Denmark consider delaying second covid vaccine dose. Guardian. 4 Jan 2020.
https://www.theguardian.com/world/2021/jan/04/germany-denmark-second-dose-covid-vaccine.

14. Branswell H. Britain takes a gamble with Covid-19 vaccines, upping the stakes for the rest of us. Stat2021.
https://www.statnews.com/2021/01/04/britain-takes-a-gamble-with-covid-19-vaccines-upping-the-stakes-for-the-rest-of-us.
15. British Society for Immunology. Statement on covid-19 vaccine dosing schedules. https://www.immunology.org/policy-and-public-
affairs/briefings-and-position-statements/COVID-19-vaccine-dosing-schedules.

I Accept
Cookies and privacy
We and our partners store and/or access information on a device, such as unique IDs in cookies to process
personal data. You may accept or manage your choices by clicking below, including your right to object where Show Purpose
legitimate interest is used, or at any time in the privacy policy page. These choices will be signaled to our
partners and will not affect browsing data. Cookie policy

We and our partners process data to provide:

Store and/or access information on a device, Personalised ads and content, ad and content measurement,
audience insights and product development, Use precise geolocation data, Actively scan device characteristics
for identification
List of Partners (vendors)

https://www.bmj.com/content/372/bmj.n18.full.print 5/5